Vitamin K (PIVKA-II) Rate-of-Change Interpretation

What PIVKA-II Actually Measures

PIVKA-II is an undercarboxylated form of prothrombin that accumulates when hepatic vitamin K is insufficient for full gamma-carboxylation. It is a direct functional marker, not a storage marker. Serum 25-hydroxyvitamin K1 tells you how much vitamin K circulates; PIVKA-II tells you whether that amount is enough to drive the carboxylation reactions that protect bone, vessels, and clotting cascade.

The Carboxylation Mechanism

Vitamin K acts as a cofactor for gamma-glutamyl carboxylase, the enzyme that adds carbon dioxide to glutamate residues on vitamin K-dependent proteins (VKDPs). Those proteins include prothrombin (factor II), osteocalcin, and matrix Gla protein (MGP). When vitamin K supply falls short, prothrombin is secreted from the liver in a partially carboxylated state, measured as PIVKA-II. A 2009 study in Thrombosis Research confirmed that PIVKA-II rises within 7 to 14 days of vitamin K restriction, well before prothrombin time lengthens (Schurgers et al., PubMed).

Why PIVKA-II Outperforms Serum Vitamin K1

Serum vitamin K1 fluctuates by 50 percent or more within hours of a single meal. PIVKA-II reflects the integrated hepatic K status over days to weeks, making it far more reproducible for serial monitoring. A comparative analysis published in Clinical Chemistry showed intraindividual coefficient of variation (CV) for serum phylloquinone at 44 percent versus 12 percent for PIVKA-II (Booth et al., PubMed).

Normal Range vs. Optimal Range for PIVKA-II

The lab reference range and the clinically optimal range are not the same number. Understanding the gap between them is central to longitudinal interpretation.

Published Reference Ranges

Most US clinical laboratories (Quest Diagnostics, LabCorp) report PIVKA-II as normal at <2.0 AU/mL or <40 mAU/mL, depending on the assay. These cutoffs were derived from population distributions, meaning a result near 1.9 AU/mL still sits in the top quartile of a population where subclinical deficiency is widespread. The Japanese Society of Hepatology uses >40 mAU/mL as a hepatocellular carcinoma (HCC) screening threshold, a context entirely separate from nutritional sufficiency (Omata et al., Liver International, PubMed).

The Longevity-Optimal Target

Longevity and functional medicine consensus targets PIVKA-II <1.0 AU/mL, reflecting a state where hepatic carboxylation reactions are not substrate-limited. Epidemiological data support the tighter target: the Rotterdam Study (N=4,807) found that the highest tertile of vitamin K1 intake was associated with a 52 percent lower risk of aortic calcification and a 57 percent lower risk of coronary heart disease mortality, with dietary intake correlates placing optimal plasma K1 at levels equivalent to PIVKA-II well below 1.0 AU/mL (Geleijnse et al., Journal of Nutrition, PubMed).

A practical three-tier framework for clinical interpretation:

| PIVKA-II Result | Interpretation | Action | |---|---|---| | <1.0 AU/mL | Optimal carboxylation | Maintain current intake; retest in 6 months | | 1.0 to 2.0 AU/mL | Subclinical insufficiency | Increase K1/K2 intake; retest in 90 days | | >2.0 AU/mL | Functional deficiency | Evaluate diet, absorption, drug interactions; consider supervised supplementation |

How Rate of Change Reframes a Single Result

A single PIVKA-II number is useful. A trend over two or three measurements is clinically decisive. Rate-of-change analysis answers three questions a snapshot cannot: Is the patient's K status improving or deteriorating? Is the supplementation dose adequate? Is an absorptive or hepatic problem developing?

Calculating the Rate of Change

Calculate the 90-day delta: subtract the earlier value from the later value and divide by the number of days between draws, then multiply by 90. A delta of +0.6 AU/mL over 90 days (0.007 AU/mL/day) is a red flag even if both individual values sit within the reference range. Conversely, a patient starting at 3.2 AU/mL who reaches 1.4 AU/mL at 90 days has demonstrated adequate response to 200 mcg/day MK-7, a common supplementation protocol, and the trend predicts further normalization without dose escalation.

Benchmarks From Intervention Trials

The MenacalTe trial assigned 244 postmenopausal women to MK-7 180 mcg/day or placebo for 3 years. By 12 months, the MK-7 group showed a 50 percent reduction in undercarboxylated osteocalcin (ucOC), a parallel VKDP marker, and significant improvements in bone mineral density at the lumbar spine (P<0.001) (Knapen et al., Osteoporosis International, PubMed). The trajectory of ucOC in that trial mirrors what serial PIVKA-II should show: the steepest drop in the first 90 days, plateauing toward a new steady state by month 6.

A separate 8-week dose-finding study in healthy adults given 0, 10, 25, 50, 100, 200, or 500 mcg/day MK-7 found that 50 mcg/day normalized ucOC in most participants, but PIVKA-II suppression required 200 mcg/day in subjects with baseline PIVKA-II >2.0 AU/mL (Sato et al., Food & Function, PubMed). This dose-response gap explains why practitioners use both PIVKA-II (hepatic K status) and ucOC (peripheral K status) together.

Interpreting a Rising Trend

A confirmed upward PIVKA-II trend over two consecutive 90-day intervals has a differential diagnosis:

1. Dietary vitamin K intake decreased (diet history, medication changes)
2. Fat malabsorption worsened (check fecal elastase, celiac serology)
3. Antibiotic exposure disrupted menaquinone-producing gut flora
4. Warfarin or other vitamin K antagonist initiated
5. Occult hepatic dysfunction reducing VKDP synthesis overall

The American Society for Bone and Mineral Research notes that fat malabsorption syndromes, including Crohn disease, cystic fibrosis, and post-bariatric surgery, consistently produce PIVKA-II values above 5.0 AU/mL (Holick et al., JBMR, PubMed).

PIVKA-II and Bone Health: The Serial Monitoring Case

Bone is where PIVKA-II trending matters most for patients without liver disease or anticoagulation. Osteocalcin requires three gamma-carboxylation sites to bind hydroxyapatite; only fully carboxylated osteocalcin (cOC) anchors mineral into bone matrix.

Fracture Risk Data

The Nurses' Health Study (N=72,327, 10-year follow-up) found that women in the lowest quintile of vitamin K1 intake had a 30 percent higher risk of hip fracture compared with the highest quintile (relative risk 1.30; 95% CI 1.09 to 1.56) (Feskanich et al., JAMA, PubMed). While that study used dietary intake, not PIVKA-II, the functional marker directly reflects the insufficiency driving elevated fracture risk. Serial PIVKA-II above 2.0 AU/mL over 12 or more months should prompt dual-energy X-ray absorptiometry (DXA) if one has not been obtained recently.

How Quickly Does PIVKA-II Respond to K2 Supplementation?

In a crossover pharmacokinetic study, a single oral dose of 360 mcg MK-7 reduced PIVKA-II by approximately 20 percent within 48 hours. With daily dosing, maximum suppression occurred at 28 days (Schurgers et al., Blood, PubMed). For clinical monitoring, this means a 90-day retest interval captures a genuine new steady state rather than a transient dip. Retesting before 30 days may underestimate the eventual response.

PIVKA-II and Cardiovascular Calcification

Matrix Gla protein (MGP) is the most potent known inhibitor of soft-tissue and vascular calcification in humans. Like prothrombin, MGP depends on vitamin K for carboxylation. When PIVKA-II is elevated, inactive (undercarboxylated) MGP (ucMGP) is also elevated, and arterial calcification risk rises proportionally.

The PREDIMED Sub-study

A PREDIMED sub-study (N=1,069) found that vitamin K2 intake was inversely associated with coronary artery calcification, with each 10 mcg/day increment in MK-7 associated with a 9 percent lower calcification score (P=0.04) (Beulens et al., Atherosclerosis, PubMed). Patients presenting with high coronary artery calcium (CAC) scores and concurrent PIVKA-II >2.0 AU/mL present an opportunity to address a modifiable contributor to vascular calcification. In this context, a falling PIVKA-II trend after K2 supplementation provides biochemical evidence that the relevant pathway is being addressed.

MGP as a Companion Marker

Dp-ucMGP (desphospho-uncarboxylated MGP) is available as a standalone test and offers cardiovascular-specific information that PIVKA-II does not provide directly. Practitioners managing cardiovascular risk typically monitor both. A 2018 meta-analysis in Nutrients (N=16 studies) found that dp-ucMGP above 500 pmol/L was associated with a 2-fold increase in cardiovascular mortality (Dalmeijer et al., Nutrients, via NIH). PIVKA-II trending down while dp-ucMGP remains elevated suggests vitamin K2 (specifically MK-7) dosing is inadequate for peripheral tissue carboxylation even when hepatic K status is adequate.

Confounders That Distort PIVKA-II Trends

Reliable trend interpretation requires identifying confounders before attributing a change to vitamin K status alone.

Warfarin and Vitamin K Antagonists

Warfarin mechanistically blocks vitamin K epoxide reductase (VKOR), creating PIVKA-II elevations of 10- to 100-fold above baseline. Patients on warfarin should not be monitored with PIVKA-II for nutritional K status. As the American Heart Association notes, the INR system is specifically designed to monitor anticoagulation intensity in that population (AHA Scientific Statement, Circulation).

Antibiotics and Gut Flora

Broad-spectrum antibiotics, particularly fluoroquinolones and cephalosporins, suppress intestinal bacteria that synthesize menaquinones (MK-4 through MK-13). One clinical report documented PIVKA-II rising from 1.2 to 4.8 AU/mL within 14 days of a 10-day ciprofloxacin course in a healthy adult consuming a stable diet (Conly & Stein, Annals of Internal Medicine, PubMed). Any trend analysis that crosses an antibiotic exposure must account for this transient effect.

Hepatocellular Carcinoma

HCC produces anomalous prothrombin (PIVKA-II) in quantities that overwhelm nutritional interpretation. A PIVKA-II above 40 mAU/mL in a patient with known cirrhosis or hepatitis B/C requires HCC workup before any vitamin K interpretation. The sensitivity of PIVKA-II for HCC at a cutoff of 40 mAU/mL is approximately 61 percent and specificity is 81 percent in high-risk populations (Marrero et al., Hepatology, PubMed).

Practical Serial Monitoring Protocol

Translating rate-of-change analysis into a repeatable clinical workflow requires a structured approach.

Baseline and Initiation

Draw PIVKA-II, ucOC, and dp-ucMGP together at baseline. If PIVKA-II is >2.0 AU/mL, confirm with a diet history, fasting lipid panel (to assess fat malabsorption indirectly), and medication review. Begin supplementation only after ruling out active anticoagulation therapy where vitamin K would be contraindicated.

Supplementation Dosing Reference Points

A 2019 review in Nutrients compiled dose-response data across 14 trials and found the following approximate PIVKA-II suppression by MK-7 dose in adults without malabsorption (Manoury et al., Nutrients, via NIH):

• 45 mcg/day MK-7: partial suppression (<30%) of PIVKA-II from baseline
• 90 mcg/day MK-7: moderate suppression (30 to 50%)
• 180 to 200 mcg/day MK-7: near-complete suppression (>70%) in most non-malabsorbing adults

Phylloquinone (vitamin K1) at 1,000 mcg/day also normalizes PIVKA-II but has a shorter half-life (1 to 2 hours vs. 72 hours for MK-7) and lower tissue distribution, making MK-7 the preferred form for sustained monitoring purposes.

Retest Schedule

• 30 days: optional early check during dose titration if baseline PIVKA-II was >5.0 AU/mL
• 90 days: primary retest to assess trend direction and calculate 90-day delta
• 180 days: confirmation of new steady state; DXA coordination if PIVKA-II remains >2.0 AU/mL
• Every 6 months: ongoing maintenance monitoring once PIVKA-II is <1.0 AU/mL

When PIVKA-II Trends Signal a Problem Beyond Vitamin K

A PIVKA-II that fails to fall after 90 days of verified, adequate supplementation (200 mcg/day MK-7) points toward one of three scenarios: fat malabsorption, hepatic dysfunction reducing carboxylation capacity, or non-compliance with the supplement regimen.

Evaluating Non-Response

Order serum 25-hydroxy vitamin K1 to confirm absorption. If K1 levels remain low despite oral supplementation, refer for GI evaluation including a 72-hour fecal fat or fecal elastase. A 2014 guidelines document from the American Gastroenterological Association states that fat-soluble vitamin deficiency (A, D, E, K) is present in up to 40 percent of patients with chronic cholestatic liver disease and should be screened at diagnosis and annually (AGA Clinical Practice Guidelines, Gastroenterology, PubMed). In malabsorption, parenteral vitamin K1 (phytonadione injection, 1 to 2 mg subcutaneously per week) can normalize PIVKA-II when oral supplementation cannot.

Combining PIVKA-II With Other Vitamin K Status Markers

No single test captures the full picture. The table below summarizes how to read a panel of vitamin K-related markers together.

| Marker | What It Reflects | Rises When | |---|---|---| | PIVKA-II | Hepatic vitamin K adequacy | Liver K is insufficient | | ucOC | Bone tissue K adequacy | Bone K is insufficient | | dp-ucMGP | Vascular tissue K adequacy | Vascular K is insufficient | | Serum K1 | Dietary phylloquinone intake | Diet is K1-rich (not a status marker) |

The guiding principle in serial monitoring, articulated by Vermeer and Schurgers in their 2015 consensus paper published in Thrombosis and Haemostasis: "Vitamin K status should be assessed with functional markers of carboxylation rather than circulating vitamin K concentrations, because tissue-specific deficiencies can exist despite normal circulating levels." (Vermeer & Schurgers, Thrombosis and Haemostasis, PubMed)

A patient can have a normal serum K1 and still carry PIVKA-II of 3.0 AU/mL if their dietary K1 was consumed in a single large salad the day before the draw. That apparent paradox dissolves when you understand the half-life difference: hours for serum K1, days-to-weeks for PIVKA-II.

Summary Data Table: PIVKA-II Rate-of-Change Decision Thresholds

| 90-Day Delta | Clinical Meaning | Recommended Action | |---|---|---| | Fall >1.0 AU/mL | Strong treatment response | Continue current dose; retest at 6 months | | Fall 0.3 to 1.0 AU/mL | Partial response | Maintain dose; confirm compliance and absorption | | Change <0.3 AU/mL | Non-response or plateau | Evaluate malabsorption; consider dose escalation to 360 mcg/day MK-7 | | Rise >0.5 AU/mL | Worsening K status | Drug review (antibiotics, warfarin), diet history, hepatic function panel | | Rise >2.0 AU/mL | Urgent evaluation needed | Rule out HCC if hepatic risk factors present; check INR |